Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adjunctive therapies in Kawasaki disease.

Literature DB >> 29076637

Adjunctive therapies in Kawasaki disease.

Abstract

Despite the administration of intravenous immunoglobulin (IVIg) at a dose of 2 g/kg, approximately 3-5% of children with acute Kawasaki disease (KD) may develop coronary artery aneurysms. IVIg-resistance, defined as recrudescence of fever more than 36 h after IVIg completion, is a risk factor for coronary artery abnormalities. Thus, several adjunctive therapies are being evaluated for use in IVIg-resistant KD patients and in patients with coronary artery abnormalities. In this review the role of some of these adjunctive therapies in treatment of children with KD is discussed.

Entities: Chemical Disease Gene Species

Keywords: anakinra; atorvastatin; cyclosporine; etanercept; infliximab; methylprednisilone

Mesh：

Substances：

Year: 2017 PMID： 29076637 PMCID： PMC5777888 DOI： 10.1111/1756-185X.13208

Source DB: PubMed Journal: Int J Rheum Dis ISSN： 1756-1841 Impact factor: 2.454

41 in total

1. miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.

Authors: Ming He; Zhen Chen; Marcy Martin; Jin Zhang; Panjamaporn Sangwung; Brian Woo; Adriana H Tremoulet; Chisato Shimizu; Mukesh K Jain; Jane C Burns; John Y-J Shyy
Journal: Circ Res Date: 2016-12-06 Impact factor: 17.367

2. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells.

Authors: Tatiane C Izidoro-Toledo; Danielle A Guimaraes; Vanessa A Belo; Raquel F Gerlach; Jose Eduardo Tanus-Santos
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2011-03-30 Impact factor: 3.000

3. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors: Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal: J Pediatr Date: 2006-08 Impact factor: 4.406

4. The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.

Authors: S Blankier; B W McCrindle; S Ito; R S M Yeung
Journal: Clin Exp Immunol Date: 2011-03-01 Impact factor: 4.330

5. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

Authors: Jane W Newburger; Lynn A Sleeper; Brian W McCrindle; L LuAnn Minich; Welton Gersony; Victoria L Vetter; Andrew M Atz; Jennifer S Li; Masato Takahashi; Annette L Baker; Steven D Colan; Paul D Mitchell; Gloria L Klein; Robert P Sundel
Journal: N Engl J Med Date: 2007-02-15 Impact factor: 91.245

6. [Cyclosporin A treatment for refractory Kawasaki disease].

Authors: Hiroyuki Suzuki; Tomohiro Suenaga; Nobuyuki Kakimoto; Takashi Takeuchi; Shoichi Shibuta
Journal: Nihon Rinsho Date: 2014-09

7. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

Authors: Adriana H Tremoulet; Sonia Jain; Preeti Jaggi; Susan Jimenez-Fernandez; Joan M Pancheri; Xiaoying Sun; John T Kanegaye; John P Kovalchin; Beth F Printz; Octavio Ramilo; Jane C Burns
Journal: Lancet Date: 2014-02-24 Impact factor: 79.321

8. Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Authors: Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns
Journal: J Pediatr Date: 2008-03-04 Impact factor: 4.406

9. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease.

Authors: Keiko Okada; Junichi Hara; Ichiro Maki; Kazunori Miki; Kouji Matsuzaki; Taro Matsuoka; Takehisa Yamamoto; Toshinori Nishigaki; Syunji Kurotobi; Tetsuya Sano
Journal: Eur J Pediatr Date: 2008-04-30 Impact factor: 3.183

10. Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease.

Authors: Chisato Shimizu; Tomoyo Matsubara; Yoshihiro Onouchi; Sonia Jain; Shelly Sun; Caroline M Nievergelt; Hiroko Shike; Victoria H Brophy; Tsuyoshi Takegawa; Susumu Furukawa; Teiji Akagi; Jane W Newburger; Annette L Baker; David Burgner; Martin L Hibberd; Sonia Davila; Michael Levin; Manju Mamtani; Weijing He; Sunil K Ahuja; Jane C Burns
Journal: J Hum Genet Date: 2010-09-09 Impact factor: 3.172

14 in total

1. Serum alanine aminotransferase level and intravenous immunoglobulin resistance in patients with kawasaki disease.

Authors: Hiroya Masuda; Ryusuke Ae; Taka-Aki Koshimizu; Koki Kosami; Nobuko Makino; Yuri Matsubara; Teppei Sasahara; Yosikazu Nakamura
Journal: Clin Rheumatol Date: 2022-07-07 Impact factor: 3.650

2. Interleukin-33/ST2 Axis as Potential Biomarker and Therapeutic Target in Kawasaki Disease.

Authors: Seigo Okada; Hiroki Yasudo; Yuji Ohnishi; Chie Matsuguma; Reiji Fukano; Takahiro Motonaga; Takako Waniishi; Shunji Hasegawa
Journal: Inflammation Date: 2022-10-08 Impact factor: 4.657

3. Differences in Sensitivity Between the Japanese and Z Score Criteria for Detecting Coronary Artery Abnormalities Resulting from Kawasaki Disease.

Authors: Ryusuke Ae; Yoshihide Shibata; Tohru Kobayashi; Koki Kosami; Masanari Kuwabara; Nobuko Makino; Yuri Matsubara; Teppei Sasahara; Hiroya Masuda; Yosikazu Nakamura
Journal: Pediatr Cardiol Date: 2022-09-19 Impact factor: 1.838

10. Elevated Levels of Pentraxin 3 Correlate With Neutrophilia and Coronary Artery Dilation During Acute Kawasaki Disease.

Authors: Lauren L Ching; Vivek R Nerurkar; Eunjung Lim; Ralph V Shohet; Marian E Melish; Andras Bratincsak
Journal: Front Pediatr Date: 2020-06-25 Impact factor: 3.418